Autogene cevumeran goes on hold in adjuvant bladder cancer.
ApexOnco Front Page
Recent articles
The deal for ISB 2001 is worth $700m up front.
AbbVie looks to justify its faith in TeneoOne, and Bristol its phase 3 move with BMS-986393.
Kura will see more combo data, while a new contender from Sumitomo emerges.
Astra squares up to Merck's Curon deal, while Novartis and Galapagos face off in fast-manufactured Car-T.
Genmab quietly reveals pipeline discontinuations and a delay to the son of Darzalex.
Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.
The company abandons TNG908, but is still all in on the troubled target.
